Abstract. Hutchinson-Gilford progeria (HGPS) is a premature aging syndrome associated with LMNA mutations. Progeria cells bearing the G608G LMNA mutation are characterized by accumulation of a mutated lamin A precursor (progerin), nuclear dysmorphism and chromatin disorganization. In cultured HGPS fi broblasts, we found worsening of the cellular phenotype with patient age, mainly consisting of increased nuclear-shape abnormalities, progerin accumulation and heterochromatin loss. Moreover, transcript distribution was altered in HGPS nuclei, as determined by different techniques. In the attempt to improve the cellular phenotype, we applied treatment with drugs either affecting protein farnesylation or chromatin arrangement. Our results show that the combined treatment with mevinolin and the histone deacetylase inhibitor trichostatin A dramatically lowers progerin levels, leading to rescue of heterochromatin organization and reorganization of transcripts in HGPS fi broblasts. These results suggest that morpho-functional defects of HGPS nuclei are directly related to progerin accumulation and can be rectifi ed by drug treatment.
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Hutchinson-Gilford progeria syndrome (HGPS, OMIM 176670) is a rare pre-mature aging disorder clinically characterized by postnatal growth retardation, midface hypoplasia, premature atherosclerosis, absence of subcutaneous fat, alopecia and generalized osteodysplasia with osteolysis and pathologic fractures [1] [2] [3] . Death occurs in the teenage usually due to coronary artery disease [2] . HGPS is caused by sporadic mutations in LMNA (OMIM 150330) coding for alternatively spliced lamins A and C.
At least fi ve different mutations within the LMNA gene have been found in patients with HGPS [3] [4] [5] . However, most HGPS-described cases harbor an identical C-to-T transition at position 1824 of the coding sequence in the context of a CpG dinucleotide [2] . This mutation results in a silent polymorphism at codon 608 within exon 11 (G608G), which causes the activation of a cryptic donor-splicing site, resulting in deletion of 150 bp in the mRNA [5] . A truncated pre-lamin A isoform is therefore translated which has been recently referred to as progerin [4, 5] . Progerin lacks 50 amino acids including the endoprotease cleavage site present at the C terminus of the 2670 M. Columbaro et al.
Recovery of chromatin organization in Hutchinson-Gilford progeria wild-type lamin A precursor [2] . Therefore, the HGPS pathogenesis is likely to arise from accumulation of the mutated 67 kDa isoform of farnesylated pre-lamin A [2] . Nuclear envelope-nuclear lamina abnormalities and loss of peripheral heterochromatin have been described in HGPS fi broblasts [6] . We observed these defects in the three cell lines examined in this study and showed that they are more represented in cell lines from older patients, concomitant with the increased appearance of progerin in those cells. In HGPS nuclei, transcript distribution was altered, while transcriptional activity was slightly decreased, despite the massive chromatin decondensation.
In an attempt to destabilize the farnesylated protein, we treated HGPS cells with a farnesyl-transferase inhibitor (mevinolin). We observed a slight decrease in the amount of progerin and rescue of heterochromatin organization in a low percentage of mevinolin-treated cells. In a second step, we attempted to restore heterochromatin areas in HGPS nuclei using drugs known to modify chromatin organization. Unexpectedly, rescue of heterochromatin organization and transcript distribution was obtained in a high percentage of HGPS fi broblasts receiving combined treatment with mevinolin and trichostatin A. This treatment also dramatically lowered the progerin level.
Materials and methods
Cell cultures. Skin fi broblast cultures from three HGPS patients carrying a G608G lamin A/C mutation were obtained from the Progeria Research Foundation, while control cultures were obtained in our laboratory from skin biopsies of unaffected controls (age 2 to 50) following written consent. Fibroblast cultures were established and cultured in Dulbecco's modifi ed Eagle's medium supplemented with 10% fetal calf serum (FCS) and antibiotics (penicillin, 50 units/ml; streptomycin, 50 mg/ml; amphotericin B, 250 µg/ml). The three HGPS cell lines were: HGADFN001 (age 9 years, passage 13), HGADFN003 (age 2 years, passage 13), HGADFN127 (age 3 years, passage 7). The experiments were performed at these passage numbers, except when stated otherwise.
Drug treatments.
To induce defarnesylation of progerin, 25 µM mevinolin (Sigma) was added to the culture medium for 18 h. The following chromatin-modifying agents were used: (i) 5-azadeoxycytidine (Sigma), (ii) anacardic acid (Sigma), (iii) trichostatin A (TSA) (Sigma). 5-Azadeoxycytidine was applied to cultured fi broblasts for 18 h following mevinolin treatment. This drug inhibits DNA methylation and, at the dosage here employed (10 µM for 18 h), elicits constitutive heterochromatin decondensation [7] . The inhibitor of histone acetyl transferases, anacardic acid, was applied to cultured fi broblasts for 18 h at 9 µM. The histone deacetylase (HDAC) inhibitor TSA (Sigma) [8] In situ transcription assay. Living fi broblasts were treated according to published protocols [10] . Briefl y, cells were permeabilized in a buffer containing 20 mM Tris-HCl (pH 7.4), 5 mM MgCl 2 , 0.5 mM EGTA, 25% glycerol, 10 µg/ml digitonin, 1 mM PMSF, RNasin (20 U/ ml). The transcription assay was performed for 5 min in a buffer containing 50 mM Tris-HCl, pH 7.4, 100 mM KCl, 10 mM MgCl 2 , 0.5 mM EGTA, 25% glycerol, 2 mM ATP, 0.5 mM CTP, 0.5 mM GTP, 0.5 mM BrUTP, 1 mM PMSF and RNasin (20 U/ml). Alpha-amanitin (10 µg/ml) (Sigma) was added to the transcription buffer to obtain negative controls (not shown). Cells were washed in PBS and fi xed in 2% paraformaldehyde at room temperature. Incorporated nucleotides were revealed by immunofl uorescence labeling with anti-BrdU antibody.
Western blot. Western blot analysis of cellular lysates from human fi broblasts was done as follows. Cells were lysed in buffer containing 10 mM Tris-HCl, pH 7.4, 1% Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate, 1 mM NaVO 3 , 150 M NaCl, 1 mM EDTA, 1 mM PMSF, 1 µM aprotinin, leupeptin, pepstatin. Proteins were loaded in Laemmli sample buffer and subjected to SDS-PAGE followed by immunochemical reactions. Immunoblotted bands were detected by enhanced chemiluminescence (Amersham).
Immunofl uorescence. Human fi broblasts grown on coverslips were fi xed in paraformaldheyde 4% in PBS at 4 °C and post-fi xed in methanol at -20 °C for 7 min. Samples were incubated with PBS containing 4% BSA to saturate non-specifi c binding. Incubation with primary antibodies was performed overnight at 4 °C, while secondary anti- bodies were applied for 1 h at room temperature. Slides were mounted with an anti-fade reagent in glycerol and observed with a Nikon E 600 fl uorescence microscope equipped with a digital camera. Pictures were elaborated with Photoshop-6 software.
Electron microscopy. Cell pellets from control and HGPS fi broblasts (subjected or not to drug treatment) were fi xed with 2.5% glutaraldehyde-0.1 M phosphate buffer pH 7.3 for 1 h at room temperature. After post-fi xation with 1% osmium tetroxide (OsO 4 ) in veronal buffer for 1 h, pellets were dehydrated in an ethanol series, infi ltrated with propylene oxide and embedded in Epon resin. Ultrathin sections (60 nm thick) were stained with uranyl acetate and lead citrate (10 min each) and were observed at 0° tilt angle with a Philips EM 400 transmission elec- Recovery of chromatin organization in Hutchinson-Gilford progeria tron microscope, operated at 100 kV. At least 200 nuclei per sample were observed. Regressive EDTA staining was carried out according to the procedure of Bernhard [11] . Briefl y, ultrathin sections of Epon-embedded control or HGPS fi broblasts (fi xed with 2.5% glutaraldehyde in phosphate buffer pH 7.3, avoiding OsO 4 post-fi xation) were fl oated for 10 min on 5% aqueous uranyl acetate at room temperature, washed with distilled water and treated with 0.2 M EDTA for 60 min. Sections were washed with distilled water and contrasted for 10 min with standard lead citrate at room temperature.
Results
Progerin accumulation in HGPS fi broblasts correlates with nuclear defects. Progerin was detected in the three examined cell lines by Western blot analysis (fi g. 1A). An increased proportion of progerin relative to mature lamin A was determined in the cell line HGADFN001 from the older patient (fi g. 1A). The lamin A/C level was reduced in HGADFN001 fi broblasts (fi g. 1A). Emerin expression was not affected in HGPS cells (fi g. 1A).
Nuclear shape was dramatically altered in HGPS fi broblasts, with enlarged nuclei characterized by invaginations and blebs (fi g. 1B). Double-immunofl uorescence labeling of HGPS fi broblasts was performed using antilamin A/C and anti-emerin antibodies. Lamin A/C and emerin mostly co-localized in progeria nuclei (fi g. 1B). Worsening of nuclear envelope defects with patient age was evident (compare HGADFN003 and HGADFN001 nuclei; fi g. 1B). Electron microscopy analysis of HGPS nuclei confi rmed the worsening of nuclear defects with patient age (fi g. 1C). Focal loss of peripheral heterochromatin was observed in most nuclei, while heterochromatin areas became almost undetectable in the older cell line (fi g. 1C). Nuclear envelope invaginations were observed (fi g. 1C).
In some instances, nuclear invaginations also contained the outer nuclear membrane (fi g. 1C; arrowheads), but more often were devoid of the outer nuclear membrane and included the perinuclear cisterna (fi g. 1C; arrows).
Methylation of H3 histone is altered in HGPS nuclei.
The methylation pattern of H3 histone was investigated in HGPS cells. Figure 2 shows immunofl uorescence labeling of mono-, di-and tri-H3K9 in HGADFN127 fi broblasts. Mono-H3K9 staining was reduced in HGPS nuclei and was moderately detectable in 10-20% of nuclei (fi g. 2A). The labeling pattern of di-H3K9 was comparable to controls (fi g. 2B), while a dramatic alteration of tri-H3K9 was observed in HGPS cells. Twenty percent of HGADFN127 nuclei were negative for tri-H3K9 staining (fi g. 2C). Even more striking alterations of labeling patterns were observed in the other HGPS cell lines (fi g. 2C, graph). These results show that both facultative heterochromatin methylation (detected by mono-H3K9 labeling) and constitutive heterochromatin methylation (revealed by tri-H3K9 staining) [12] are altered in HGPS.
Progerin accumulation is reduced by mevinolin treatment. In the attempt to destabilize progerin, we used mevinolin to obtain defarnesylation. Figure 3A shows the WB analysis of progerin in HGPS fi broblasts subjected to mevinolin treatment. Control fi broblasts were also treated with the farnesyltransferase inhibitor and subjected to Western blot analysis using anti-lamin A/C antibody (fi g. 3) and anti-pre-lamin A antibody (not shown). Beside the expected increase in wild-type pre- lamin A caused by mevinolin in all the examined cell lines, a decrease in the amount of progerin was observed in HGPS lysates (fi g. 3A). The lamin A level was slightly reduced by mevinolin treatment, while amounts of lamin C and emerin were not affected (fi g. 3A).
Progerin accumulation is abolished by mevinolin/TSA treatment. In the attempt to investigate heterochromatin dynamics in HGPS nuclei, we treated HGPS fi broblasts with a set of drugs capable of interfering with chromatin organization. The effect of each treatment on progerin accumulation was evaluated by WB analysis (fi g. 3B). Treatment of progeria fi broblasts with 5-azadeoxycytidine slightly increased the amount of progerin (not shown). TSA treatment of HGPS fi broblasts slightly affected the progerin level (fi g. 3B, lane 9). Addition of each chromatin-modifying drug to mevinolin-treated cells elicited the following effects. 5-Azadeoxycytidine addition lowered wild-type pre-lamin A levels both in control and HGPS cells (fi g. 3B, lane 7 and 10). Dramatic lowering of the progerin level was observed in HGPS cells sequen-Recovery of chromatin organization in Hutchinson-Gilford progeria ardic acid elicited effects on progerin and mature lamin A expression, which, however, were not consistent and require further investigation (not shown). We performed a statistical evaluation of wild-type pre-lamin A and progertially treated with mevinolin and TSA (fi g. 3B, lane 8). A moderate reduction in wild-type pre-lamin A was also observed in these cells, while lamin A and C levels were slightly affected by TSA addition (fi g. 3B, lane 8). Anac- in densitometric values referred to immunoblotted bands (fi g. 3C). A signifi cant decrease in progerin accumulation is clearly obtained by mevinolin/TSA administration (fi g. 3C). The overall evaluation of graphs shows that each drug treatment elicited very different effects on wild-type compared to mutated lamin A precursor (fi g. 3C).
Heterochromatin organization in HGPS nuclei is improved by mevinolin/TSA treatment. By ultrastructural analysis, heterochromatin areas were not detected in untreated HGADFN001 fi broblasts (fi g. 4A), while they were observed at the nuclear periphery in 5% of mevinolin-treated HGADFN001 fi broblasts (fi g. 4B). However, mevinolin treatment of HGPS fi broblasts apparently failed to improve nuclear shape abnormalities (not shown). TSA alone did not cause detectable changes in chromatin organization in control or in HGPS cells (fi g. 4C). In all the examined HGPS cell lines, administration of mevinolin plus TSA elicited reorganization of peripheral heterochromatin (fi g. 4D). Nuclear shape was also improved after the combined treatment with mevinolin and TSA (fi g. 4D).
To support the reported fi ndings, we checked the distribution of tri-H3K9 before and after mevinolin/TSA treatment. Tri-H3K9 stained discrete sites in control nuclei, but labeling was not detected in most HGPS nuclei (fi g. Figure 4G shows the statistical analysis of the experiments shown in Figure 4E . The percentage of HGPS nuclei showing tri-H3K9 staining is increased to almost 100% by mevinolin/TSA treatment (fi g. 4G).
Ribonucleoprotein levels are reduced in HGPS cells
and restored by mevinolin/TSA treatment. We sought to determine if the increased availability of dispersed chromatin could affect the transcriptional activity of HGPS nuclei. In particular, we wished to determine if dispersed chromatin areas observed by electron microscopy corresponded to domains of increased transcript accumulation. An altered distribution of mRNA transcripts was revealed by an in situ transcription assay. Control nuclei showed a uniform staining of BrU all over the nucleus (fi g. 5A). The amount of incorporated BrU was reduced in enlarged HGPS nuclei showing major nuclear lamina defects and BrU-containing transcripts were distributed in the nucleus with a non-uniform pattern (fi g. 5A). After treatment with mevinolin and TSA, BrU incorporation was comparable to controls in most HGPS nuclei, including some enlarged nuclei (fi g. 5A). Uniform BrU staining was observed in HGPS nuclei after mevinolin/TSA treatment (fi g. 5A). Reverse EDTA staining of control nuclei allowed us to identify ribonucleoproteins distributed to discrete clusters throughout the nuclei except at the nuclear periphery, where bleached chromatin was evident (fi g. 5B, control). In mevinolin/TSA-treated control nuclei, a uniform distribution of transcripts all over the nucleus was observed (fi g. 5B, mevinolin/TSA control). Ribonucleoprotein staining was dramatically reduced in 36% of HGPS nuclei and a faint gray staining was observed throughout the nucleus, including the nuclear periphery (fi g. 5B, untreated HGPS). Bleached chromatin areas at the nuclear lamina were absent, while an irregular thickening of the lamina was revealed (fi g. 5B, arrows). Mevinolin/TSA treatment of HGPS cells restored the ribonucleoprotein distribution (fi g. 5B, mevinolin/TSA HGPS) and improved nuclear lamina organization leading to rescue of heterochromatin areas (arrowheads). An altered distribution of intranuclear lamin A associated with splicing factor compartments was observed in all HGPS cell lines (fi g. 5C). Mevinolin/TSA treatment restored the intranuclear lamin A labeling pattern in HGPS nuclei (fi g. 5C).
Discussion
The results reported in this study show that progerin accumulation, nuclear envelope alterations and chromatin disorganization in HGPS correlate with patient age and are associated with defects of transcript accumulation and distribution. We demonstrate that both nuclear-shape abnormalities and heterochromatin organization may be rescued by treating HGPS fi broblasts with a farnesyltransferase inhibitor, followed by a chromatin-modifying drug. Reversal of the nuclear defects is related to lowering of the progerin level in drug-treated samples and also elicits recovery of the ribonucleoprotein staining pattern. Worsening of the HGPS cellular phenotype with patient age is clearly shown by the formation of nuclear introfl ections, blebs and enlargement of nuclei, as well as by progressive loss of peripheral heterochromatin. These aspects are related to the increased proportion of progerin relative to mature lamin A found in HGPS cells from older patients. On the other hand, a combination of factors is likely to cause the progressive worsening of nuclear defects observed in HGPS. In our hands, fi broblasts from the 3-year-old patient are in fact less affected than those from the 2-year-old patient (which are at a higher passage number). We suggest that both passage number [6] and patient age contribute to worsening of the cellular phenotype. However, we cannot rule out the possibility 2676 M. Columbaro et al.
Recovery of chromatin organization in Hutchinson-Gilford progeria of an involvement of the genetic background in the different severity of the cellular defects observed in HGPS cells from different patients. Although we observe a slight reduction in mature lamin A in the older patient cell line, literature data [13, 14] and our results obtained in the present study strongly suggest that the severe defects of HGPS cells are due to progerin accumulation. Here we show that removal of progerin from HGPS fi broblasts can be obtained by drug treatment and is associated with an important improvement in the cellular phenotype. As expected, wild-type pre-lamin A also accumulates in mevinolin/TSA-treated cells. This could be expected to elicit a toxic effect, as wild-type prelamin A has been shown to be toxic for transgenic mice [9, 13, 15] and humans [16] [17] [18] . However, it is worth noting that, after mevinolin treatment, a non-farnesylated lamin A precursor accumulates. This protein elicits very different effects on heterochromatin organization and on the whole cellular phenotype in comparison to farnesylated pre-lamin A [G. Lattanzi et al., unpublished results], as suggested by Fong et al. [13] .
Results obtained by drug treatments further confi rm that the amount of progerin accumulated in each HGPS cell culture directly determines the severity of the cellular phenotype. In fact, a slight reduction of progerin level by mevinolin corresponds to recovery of heterochromatin organization in a minor (though signifi cant) proportion of cells. On the other hand, recovery of the heterochromatin arrangement along with improvement of nuclear-shape abnormalities is observed in a high percentage of HGPS cells after progerin removal. It should be noted that TSA was effective in reducing the progerin level only in mevinolin-pretreated cells, indicating that defarnesylation of the mutated protein allows destabilization. This aspect is a crucial point in the understanding of HGPS pathogenesis. Recently published papers [19] [20] [21] [22] show that farnesyl-transferase inhibitors cause relocalization of progerin at the nuclear interior. This effect appears to improve nuclear shape [19] [20] [21] [22] . These and our results suggest that defarnesylation of progerin represents the fi rst step toward an improvement of the cellular phenotype. Release of the mutated protein from one nuclear region to another appears to be the fi rst effect of progerin defarnesylation [19] [20] [21] [22] . The subsequent reduction in progerin level we obtained by TSA addition more likely affects newly established protein interactions (see below). The major role of progerin in the HGPS pathogenetic mechanism is also supported by other recently published data [14] showing that recovery of the nuclear phenotype is obtained in HGPS fi broblasts by correction of the aberrant LMNA splicing leading to reduced progerin transcription [14] . Increased HDAC activity and increased levels of HDACs bound to unphosphorylated pRB (the protein product of the retinoblastoma gene) have been found in senescent cells [8] . TSA, which inhibits HDAC activity, has been suggested to reverse the cellular phenotype from senescent to proliferating by activating the cyclin E promoter [8] . We cannot completely rule out the possibility that pre-lamin A (and/or progerin) might be involved in the protein complex including pRB, HDACs and the E2F transcription factor to affect the stability of the protein complex itself. Lamin A does in fact interact with pRB and E2F in the protein complex anchored by the laminaassociated polypeptide 2 alpha (LAP2a) [23] . However, the reason why TSA does not elicit the expected decondensation effect on chromatin in HGPS nuclei is not obvious. We hypothesize either an altered distribution of chromatin-regulating factors including HDACs, or a mislocalization of mutated lamin A precursor affecting the composition of chromatin-regulating complexes in HGPS. Both these situations might explain the unexpected effects produced by inhibition of HDACs. Our results suggest that mevinolin/TSA treatment leads to progerin degradation rather than to impairment of progerin synthesis. The fi nding that mevinolin /TSA treatment reduces the progerin level, while wild-type pre-lamin A is not or only minimally affected suggests that there is not a down-regulation of pre-lamin A expression. Moreover, the amount of progerin is dramatically reduced only in cells pretreated with mevinolin. This strongly suggests that defarnesylation of progerin is necessary to obtain protein loss. The reported data argue for a major role of progerin in chromatin organization and dynamics. Our results also suggest a role for wild-type pre-lamin A in heterochromatin dynamics. For example, we observed a dramatic decrease in pre-lamin A accumulation in cells treated with the chromatin demethylating agent 5-azadeoxycitidine. Interestingly, a role for pre-lamin A in the organization of chromatin domains has been suggested [24, 25] and a DNA-binding domain in the lamin A carboxy-terminus sequence has been determined [26] . Moreover, heterochromatin defects feature in all the laminopathies described so far [6, 10, [27] [28] [29] [30] . Evidence of pre-lamin A involvement in chromatin dynamics will be presented in another study [G. Lattanzi et al., unpublished results].
